Malignant tumors, including triple‐negative breast cancer cells, re‐expressing oncofetal HMGA2 frequently develop therapeutic resistance to antitumor treatments and have a poor prognosis (Sun et al., 2014; Wend et al., 2013). Here, HMGA2 is linked to cancer.